July 1, 2005Expert Review of Cardiovascular Therapy
Ximelagatran for stroke prevention in atrial fibrillation
Why the study?
Does ximelagatran prevent stroke and embolic events in patients with nonvalvular atrial fibrillation compared to warfarin?
Population
Patients with nonvalvular atrial fibrillation
Comparison
Ximelagatran (fixed twice-daily dose) vs Warfarin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Ximelagatran's hepatotoxicity precludes clinical use in atrial fibrillation despite noninferiority to warfarin; leaves open safer oral anticoagulants.
Structured PICO
Does ximelagatran prevent stroke and embolic events in patients with nonvalvular atrial fibrillation compared to warfarin?
P
Population
Patients with nonvalvular atrial fibrillation
I
Intervention
Ximelagatran (fixed twice-daily dose)
C
Comparator
Warfarin
O
Outcome
Prevention of stroke and embolic eventshard clinical
Although ximelagatran is noninferior to warfarin for stroke prevention in atrial fibrillation, its clinical utility is severely limited by hepatotoxicity.
Cite This Study
Boos et al. (2005) studied this question.